Adynxx (OTCMKTS:ADYX – Get Rating) and iCAD (NASDAQ:ICAD – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Volatility & Risk
Adynxx has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500. Comparatively, iCAD has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Earnings and Valuation
This table compares Adynxx and iCAD’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Adynxx | N/A | N/A | N/A | N/A | N/A |
| iCAD | $27.94 million | 1.35 | -$13.66 million | ($0.53) | -2.79 |
Institutional and Insider Ownership
48.0% of iCAD shares are held by institutional investors. 17.4% of Adynxx shares are held by company insiders. Comparatively, 13.5% of iCAD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and price targets for Adynxx and iCAD, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Adynxx | 0 | 0 | 0 | 0 | N/A |
| iCAD | 0 | 0 | 4 | 0 | 3.00 |
iCAD has a consensus target price of $4.50, indicating a potential upside of 204.05%. Given iCAD’s higher probable upside, analysts plainly believe iCAD is more favorable than Adynxx.
Profitability
This table compares Adynxx and iCAD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Adynxx | N/A | N/A | N/A |
| iCAD | -48.87% | -34.47% | -24.17% |
Summary
Adynxx beats iCAD on 5 of the 9 factors compared between the two stocks.
About Adynxx
Adynxx, Inc. is a clinical stage biopharmaceutical company. It engages in the manufacture, development, and sale of novel, disease-modifying products for the treatment of pain and inflammation. The company was founded by Julien Mamet in October, 2007 and is headquartered in San Francisco, CA.
About iCAD
iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.
Receive News & Ratings for Adynxx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adynxx and related companies with MarketBeat.com's FREE daily email newsletter.
